Precise® Molecular Residual Disease (MRD) Test

The Precise MRD Test from Myriad Oncology is a tumor-informed assay that is whole genome sequencing (WGS)-based, allowing it to be ultra-sensitive. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity, ensuring exceptional performance.1 The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance.​

This test is currently available for research use only (RUO).

Why a Myriad Oncology MRD Test

Precise MRD test is an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low tumor shedding cancers, such as breast, ovarian, and renal cancer. It has high sensitivity and specificity, among the best available.1

Our collaborations with leading organizations and investigators are crucial in advancing ultra-sensitive MRD testing for cancer treatment and monitoring.

See the overview of Myriad Oncology’s Precise MRD test from Chief Scientific Officer, Dale Muzzey, PhD

Precise MRD will help to answer two main questions in several key cancer types:

1

Is the cancer treatment working for my patient?

2

Has my patient’s cancer recurred?

Interim results of the MONSTAR-SCREEN-3 study presented at the ASCO 2025 Annual Meeting.

In collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, the interim results demonstrated successful pan-cancer implementation of Myriad’s ultra-sensitive Precise MRD Test to detect and monitor ctDNA in patients:

“Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests. In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection.”

- Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East (NCCHE), Japan, and principal investigator for the MONSTAR-SCREEN-3 study

Learn more

Myriad supports MRD investigator-initiated trials and other clinical study/trials.
For outreach related to partnering on new or ongoing MRD studies/trials, please contact [email protected]

For investor relations outreach, please contact [email protected]

Precise MRD Press Releases

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

June 02, 2025 | Products | Pipeline

Read more
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

May 27, 2025 | Products | Pipeline

Read more
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Apr 25, 2025 | Products

Read more
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Jan 07, 2025 | Products | Corporate

Read more
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Dec 09, 2024 | Products

Read more
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Oct 08, 2024 | Products

Read more
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Oct 01, 2024 | Products | Corporate

Read more
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

July 11, 2024

Read more
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

July 9, 2024

Read more
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

March 21, 2024

Read more
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

February 27, 2024

Read more
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

September 18, 2023

Read more
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

June 12, 2023

Read more

Featured MRD test research:

Impact of Panel Size on Molecular Residual Disease (MRD) Assay Performance

Featured MRD test research poster

Explore Myriad Oncology's portfolio of products and services

Reference:

  1. Acevedo, A. et al. Analytical validation of a high-definition tumor-informed MRD assay demonstrates robust detection at low tumor fractionscommon in breast cancer. Poster presented at the San Antonio Breast Cancer Symposium (SABCS) Dec 10-13, 2024.